Floatz logo

Montelukast

Sickle Cell Disease

Great Ormond Street Hospital for Children NHS Foundation TrustSmall moleculePhase 2/3Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

132 Active assets in the Sickle Cell Disease cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 4BB
Magnesium Metallicum
Medical College of Wisconsin
Phase 3BB
Crizanlizumab
Novartis Pharmaceuticals
Phase 4BB
Nivestim
St. Jude Children's Research Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Montelukast is also rated in:

asthmaActive
BBB
Indicative · Phase 4
73 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
BBB
Indicative · Phase 4
73 / 100
View asset →
Fabry diseaseActive
BB
Indicative · Phase 4
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →